Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin

BACKGROUND: Treatment of advanced follicular thyroid carcinoma (FTC) is based primarily on indirect evidence obtained with multikinase inhibitors (MKI) in clinical trials in which papillary carcinomas represent the vast majority of cases. However, it should be noted that MKI have a non-negligible to...

Descripción completa

Detalles Bibliográficos
Autores principales: Dias, Daniela, Damásio, Inês, Marques, Pedro, Simões, Helder, Rodrigues, Ricardo, Cavaco, Branca Maria, Leite, Valeriano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235920/
https://www.ncbi.nlm.nih.gov/pubmed/36976625
http://dx.doi.org/10.1530/ETJ-22-0227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235920/
https://www.ncbi.nlm.nih.gov/pubmed/36976625
http://dx.doi.org/10.1530/ETJ-22-0227

Ejemplares similares